533 results on '"Calvaruso, Vincenza"'
Search Results
2. Real-world experience with long-term albumin in patients with cirrhosis and ascites☆
3. Deep Learning helps discriminating Autoimmune Hepatitis and Primary Biliary Cholangitis
4. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis
5. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease
6. Preventing (First) Decompensation: Consensus Statements of Panel 5
7. Evaluation of the Role of Jaundice in the Definition of Decompensation in the Compensated Patients
8. Prevention of First Decompensation: Questionnaire
9. SAT-113 Long-term therapy with intravenous human albumin increase survival in patients with decompensated cirrhosis and refractory ascites
10. OS-096-YI Spleen stiffness measurement by transient elastography at 100 Hz refines the non-invasive diagnosis of clinically significant portal hypertension in compensated advanced chronic liver diseasefinal results of a european multicenter study
11. WED-457-YI Eliminating hcv infection from prisons in Sicily: the sintesi project (*)
12. FRI-047-YI Predictors of ascites resolution in patients with cirrhosis receiving long-term albumin treatment. Results from a real-world study in Italy (Real-ANSWER)
13. THU-101 Non-invasive tests for ruling out high-risk esophageal varices in patients with primary biliary cholangitis based on the cholestasis degree
14. LBP-038 Expanding knowledge regarding real-world treatment of patients with primary biliary cholangitis with obeticholic acid from the Italian RECAPITULATE cohort
15. OS-017 Deep learning discriminates autoimmune hepatitis and primary biliary cholangitis
16. THU-093 Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid
17. OS-016 Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVEtrial
18. Development and validation of a scoring system to predict response to obeticholic acid in primary biliary cholangitis.
19. Primary biliary cholangitis: perception and expectation of illness
20. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort
21. Quantitative Evaluation by Digital Pathology of Immunohistochemical Expression of CK7, CK19, and EpCAM in Advanced Stages of NASH
22. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)
23. Real-world experience with obeticholic acid in patients with primary biliary cholangitis
24. Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study
25. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
26. Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review.
27. Inflammation and autonomic balance in cirrhosis: Association between sympathetic nervous system and osteopontin, interleukin‐22, interleukin‐6 and interleukin‐1Ra concentrations according to portal hypertension and disease severity
28. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients
29. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals
30. Depth effect on point shear wave velocity elastography: Evidence in a chronic hepatitis C patient cohort.
31. Depth effect on point shear wave velocity elastography: Evidence in a chronic hepatitis C patient cohort
32. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis
33. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents
34. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis
35. Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients
36. Predictors of Re-bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS)
37. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort
38. Prognostic significance of liver stiffness progression in primary biliary cholangitis
39. Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study)
40. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced non-alcoholic fatty liver disease
41. Long-term outcomes of patients with chronic HBsAg positive/HBe-negative infection: differences and transition between inactive carriers and low viremic carriers
42. RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease
43. Risk factors for viral reactivation in patients with overt or occult HepatitisB Virus infection receiving immunosuppressive treatments: a systematic review and meta-analysis
44. Long-term real-world experience with obeticholic acid in primary biliary cholangitis: the Italian recapitulate study
45. Development and validation of a score predicting response to obeticholic acid in primary biliary cholangitis: the OCA response score (ORS)
46. Efficacy and safety of lusutrombopag in a real-world Italian series of cirrhotic patients with severe thrombocytopenia undergoing invasive procedures: the Reality study
47. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study
48. Predicting de‐novoportal vein thrombosis after HCV eradication: A long‐term competing risk analysis in the ongoing PITER cohort
49. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel
50. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.